Investor Relations

News Release Details

Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 26, 2020

MARLBOROUGH, Mass., Oct. 26, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by two development partners, AgonOx, Inc. and the Helmholtz Zentrum München, at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020.

Photo -  

Poster details are as follows:

Poster Sponsor:

Phio Pharmaceuticals 


Combination intratumoral treatment with INTASYL™ self-delivering RNAi
targeting TIGIT and PD-1/PD-L1 improves tumor control compared to
monotherapy in a CT26 model of murine colorectal cancer


Benjamin Cuiffo, et al.

Abstract Number:


Poster Sponsor:

AgonOx, Inc. 


Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by
gene silencing of PD1 with self-delivering RNAi INTASYLTM


Colin J. Thalhofer, et al.

Abstract Number:


Poster Sponsor: 

Helmholtz Zentrum München


New checkpoints controlling function of cytotoxic lymphocytes infiltrating human carcinoma


Anna Herbstritt, et al.

Abstract Number:


An archived version of the Phio presentation will be made available on the "Investors – Events and Presentations" section of the Company's website (click here).

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website,

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the impact to our business and operations by the recent coronavirus outbreak, results from our preclinical and clinical activities, the development of our product candidates, the ability to obtain future financing, the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law. 

Contact Phio Pharmaceuticals Corp. 

Investor Contact
Ashley R. Robinson 
LifeSci Advisors 

Cision View original content:

SOURCE Phio Pharmaceuticals Corp.